News Archive

The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams

ROCKVILLE, Md., May 11, 2022 /PRNewswire/ — Emmes – a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces that it will introduce to market its third generation version of Advantage eClinical at Society for Clinical Trials (SCT) in San Diego, May 15th – 18th. The cloud platform of Advantage eClinical will be available as a standalone software product after undergoing more than two years of development. The system has been specifically designed to provide fast study builds, greater flexibility, and insights to clinical trial sponsors of all sizes.

New blockchain talent marketplace seeks to solve hiring and diversity challenges in the rapidly growing biotech industry.

BALTIMORE, MD (May 10, 2022) – BioBuzz Media, the go-to community platform for biotech job seekers and industry professionals looking to access employers and plug into regional biotech communities, today announced its completion of the inaugural University of Maryland Blockchain Accelerator program. BioBuzz and other participating companies pitched to more than 70 attendees, including investors, mentors and industry leaders at Demo Day on May 4, 2022.

Selected from over 60 applicants to be one of eight startups in the inaugural cohort, BioBuzz is building a blockchain-based next-generation talent marketplace to de-risk hires and equitably expand the life sciences workforce. The new solution promises to provide employers with a more efficient recruiting process while providing job seekers with control of their data through a federated layer and enabling them to earn rewards for learning, training and contributing to the marketplace.

COLLEGE PARK, Md., May 10, 2022 /PRNewswire/ — The University of Maryland today dedicated the new E.A. Fernandez IDEA (Innovate, Design and Engineer for America) Factory. Designed to foster technology innovations and advances through collaboration across engineering, the arts, business and science, the A. James Clark School of Engineering’s new 60,000-square-foot building is the university’s only facility funded entirely by private philanthropy.

Image: The University of Maryland Adds $67M IDEA Factory To Its Innovation Ecosystem – https://www.prnewswire.com

We are very excited for this year’s conference theme!  Our theme will be a “green thread” that is woven throughout our many sessions to bring a fresh and holistic view into the future of HEOR in patient-driven digital healthcare systems.

The last two years have seen a rapid rise of real-time solutions, digital healthcare interactions and an accelerated expansion of mobile healthcare. As digital systems mature and incorporate a broader array of patient-reported outcomes and preference measures, the trajectory of adoption of new services will be influenced by better information on how they are affecting patients’ lives. Such as:

Image: https://www.ispor.org

GAITHERSBURG, Md., May 10, 2022  – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (MG) today at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders.  The conference is in Miami, May 10–12, 2022.

The oral presentation, “RNA CAR T-cell Therapy for Myasthenia Gravis,” will be delivered today, Tuesday, May 10 at 10:50 a.m. ET by principal investigator Volkan Granit, M.D., of the University of Miami. A poster, “Phase 1b/2a Study of Autologous mRNA-Engineered Anti- B-cell Maturation Antigen Chimeric Antigen Receptor T-cells for Treatment of Severe Generalized Myasthenia Gravis,” will be presented at the conference today and tomorrow.

There is no doubt that Virginia is open for business to the life sciences industry. Over the past several years, the state has seen significant growth in pocket ecosystems across the land, particularly in areas like Charlottesville, Richmond, and Blacksburg.

Some of the growth has been fueled by an infusion of federal monies related to the government’s efforts to mitigate the COVID-19 pandemic, while other growth has been driven by old-fashioned scientific innovation. Across the Old Dominion state, companies are driving research and development of novel therapies and more as they all combine their forces to bolster the life sciences ecosystem.

The Labs at Belward, located at the Belward Campus of The Johns Hopkins University, will Initially Provide 757,000 SF of Trophy Lab and R&D Facilities and Community Serving Amenities

Trammell Crow Company (TCC), a global commercial real estate developer, today unveiled plans to develop The Labs at Belward, a world-class life science campus, in the Shady Grove area of Montgomery County, Md. The Labs at Belward, located at the Belward Campus of The Johns Hopkins University, will initially include 757,000 square feet of trophy lab and research and discovery space across three buildings. The project has the potential to grow to approximately 1.6 million square feet across seven buildings. Construction of the initial 757,000 square feet will begin June 2023 and is slated to be completed in early 2025.

The pace at which venture capitalists are deploying funding across the globe slowed yet again in April.

Venture capital dollar volume, as tracked by Crunchbase News in a new report, peaked in November 2021. Since that apogee, the value of venture investments has ticked lower in most months before dropping another $5 billion from March to April.

Image: Nigel Sussman

COLLEGE PARK, Md. (PRWEB) May 05, 2022

Ultrasound data displayed directly on a patient via augmented reality headsets. Immersive “grand rounds” for medical students and faculty even when they’re in different locations. Virtual reality landscapes matched with classical opera to transport people with painful injuries outside of themselves, reducing the need for potentially addictive opioids.

These medical examples of extended reality (XR)–the umbrella term used for technology based in virtual and augmented reality or other immersive media–are already being prototyped or tested in clinical trials. But its widespread use in hospitals and other health care settings is currently hampered by technical challenges and sparse regulatory guidelines.